265 related articles for article (PubMed ID: 29758466)
1. Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors.
Mitra S; Dash R
J Mol Graph Model; 2018 Aug; 83():42-52. PubMed ID: 29758466
[TBL] [Abstract][Full Text] [Related]
2. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
3. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
4. In silico quest of selective naphthyl-based CREBBP bromodomain inhibitor.
Dash R; Mitra S; Arifuzzaman M; Zahid Hosen SM
In Silico Pharmacol; 2018; 6(1):1. PubMed ID: 30607314
[TBL] [Abstract][Full Text] [Related]
5. Insight into the key interactions of bromodomain inhibitors based on molecular docking, interaction fingerprinting, molecular dynamics and binding free energy calculation.
Ran T; Zhang Z; Liu K; Lu Y; Li H; Xu J; Xiong X; Zhang Y; Xu A; Lu S; Liu H; Lu T; Chen Y
Mol Biosyst; 2015 May; 11(5):1295-304. PubMed ID: 25758752
[TBL] [Abstract][Full Text] [Related]
6. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking and dynamics simulation study of flavonoids as BET bromodomain inhibitors.
Raj U; Kumar H; Varadwaj PK
J Biomol Struct Dyn; 2017 Aug; 35(11):2351-2362. PubMed ID: 27494802
[TBL] [Abstract][Full Text] [Related]
9. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based in silico screening of bromodomain ligands.
Spiliotopoulos D; Caflisch A
Drug Discov Today Technol; 2016 Mar; 19():81-90. PubMed ID: 27769362
[TBL] [Abstract][Full Text] [Related]
11. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Choubey SK; Jeyaraman J
J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
[TBL] [Abstract][Full Text] [Related]
12. A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction.
Rooney TP; Filippakopoulos P; Fedorov O; Picaud S; Cortopassi WA; Hay DA; Martin S; Tumber A; Rogers CM; Philpott M; Wang M; Thompson AL; Heightman TD; Pryde DC; Cook A; Paton RS; Müller S; Knapp S; Brennan PE; Conway SJ
Angew Chem Int Ed Engl; 2014 Jun; 53(24):6126-30. PubMed ID: 24821300
[TBL] [Abstract][Full Text] [Related]
13. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
14. A computational insight into binding modes of inhibitors XD29, XD35, and XD28 to bromodomain-containing protein 4 based on molecular dynamics simulations.
Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
J Biomol Struct Dyn; 2018 Apr; 36(5):1212-1224. PubMed ID: 28466681
[TBL] [Abstract][Full Text] [Related]
15. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
16. Does bromodomain flexibility influence histone recognition?
Steiner S; Magno A; Huang D; Caflisch A
FEBS Lett; 2013 Jul; 587(14):2158-63. PubMed ID: 23711371
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
[TBL] [Abstract][Full Text] [Related]
18. Cation-π interactions in CREBBP bromodomain inhibition: an electrostatic model for small-molecule binding affinity and selectivity.
Cortopassi WA; Kumar K; Paton RS
Org Biomol Chem; 2016 Nov; 14(46):10926-10938. PubMed ID: 27814427
[TBL] [Abstract][Full Text] [Related]
19. Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.
Almeida MO; Costa CHS; Gomes GC; Lameira J; Alves CN; Honorio KM
J Biomol Struct Dyn; 2018 Nov; 36(15):4010-4022. PubMed ID: 29132261
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of inhibitor bindings to bromodomain-containing protein 9 explored based on molecular dynamics simulations and calculations of binding free energies.
Wang Y; Wang LF; Zhang LL; Sun HB; Zhao J
SAR QSAR Environ Res; 2020 Feb; 31(2):149-170. PubMed ID: 31851834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
